SBSean S. Brummel

Sean S. Brummel

*This is an algorithmically generated author record based on publicly available information.

Sean S. Brummel has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of Perinatal HIV Exposure and HIV Disease Severity With BP in Youth

    by Tammy M. Brady, Wendy Yu, Denise L. Jacobson, Sean S. Brummel, Steven E. Lipshultz, Steven D. Colan, Paige L. Williams, Jennifer Jao, Tzy-Jyun Yao, Russell Van Dyke, et al.

    BACKGROUND: HIV infection is associated with cardiovascular events in adults. We compared mean blood pressure (BP) obtained at study visits between youth with/without perinatally acquired HIV infection and evaluated whether HIV disease severity was associated with BP. METHODS: BP was compared between participants with/without HIV in the Adolescent Master Protocol of the Pediatric HIV/AIDS Cohort Study. Marginal repeated measures analyses using generalized estimating equations evaluated the association of HIV disease severity with BP index (mean BP/95th percentile BP) and abnormal BP. RESULTS: 447 youth with HIV and 226 youth without HIV were included. Youth with HIV were more often Black non-Hispanic (66% versus 54%), had greater household income (54% versus 35%), and lower measures of adiposity than those without. Systolic BP was similar between groups, but mean diastolic BP was lower for preadolescents (63.3 mm Hg [95% CI, 59.0–67.0] versus 65.0 [61.5–68.7]) with HIV. Although youth with HIV had lower diastolic BP index (−0.011 [95% CI, −0.021 to −0.001]) and lower prevalence of abnormal BP (odds ratio, 0.78 [95% CI, 0.62–0.97]) at study visits in initial adjusted models, these associations were attenuated after adjustment for body mass index (−0.007 [95% CI, −0.017 to 0.003], odds ratio, 0.94 [95% CI, 0.76, 1.17], respectively). HIV disease severity was not associated with systolic or diastolic BP. CONCLUSIONS: Youth with HIV had lower adiposity and BP than youth without HIV during study visits. Although youth with HIV had a lower risk of abnormal BP, this association did not persist after adjustment for adiposity. Prevention and treatment of other traditional cardiovascular disease risk factors remain important among youth living with HIV.

  • Open Access

    Investigating Pace of Biological Aging as a Mental and Physical Health Biomarker in Youth with Perinatally-Acquired HIV

    by Hansoo Chang, Ashni Kumar, Joshua Suh, Kevin Street, Ana Ferariu, Alexei Taylor, Kunjal Patel, Sean Brummel, Paige Williams, Lei Wang, et al.

  • HIV Resistance to Dolutegravir Varies With Coadministered Agents

    by Ingrid A Beck, Ceejay L Boyce, Marley D Bishop, Alyssa R Oldroyd, Louise du Toit, Amashnee Saimen, Kholofelo Mn Ramarope, Sonia Hitchcock, Nicolette M du Plessis, Loice Mbogo, et al.

    We hypothesized that HIV-dolutegravir resistance is more frequent when coadministered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200 c/mL) participants from 4 cohorts (N = 660 participants) found dolutegravir resistance in 21 (11.5%). Dolutegravir resistance was greater with dolutegravir + lamivudine + zidovudine/(1 on stavudine) (odds ratio [OR] = 19.4, 95% confidence interval [CI]: 5.1–74.3) or dolutegravir + lamivudine +abacavir (OR = 5.4, 95% CI: 1.1–25.8), compared with dolutegravir + lamivudine + tenofovir.


  • A lesson in embracing uncertainty in early safety signals from the Tsepamo study

    by Sean S. Brummel, Sonja Swanson, Ellen Caniglia, Shahin Lockman, Rebecca Zash, Roger Shapiro

    Objective: We investigated how randomness may have contributed to the apparent decline in observed risk of neural tube defects (NTDs) following in-utero dolutegravir (DTG) exposure. We aimed to describe statistical approaches to uncertainty using accessible language for nonstatistical audiences. Methods: We reanalyzed Tsepamo Study data using frequentist confidence intervals, repeated intervals accounting for group sequential monitoring, and Bayesian posterior and posterior predictive distributions. We estimated the probability of decision reversal using simulation. Results: The initial Tsepamo analysis reported a large difference in NTD risk between DTG and non-DTG exposures, with point estimates of 0.94 and 0.12%, respectively. This difference diminished with subsequent data, with updated estimates of 0.10% for DTG and 0.11% for non-DTG exposures. Our analyses showed the early finding was statistically compatible with a wide range of effect sizes, including no difference. Due to the large uncertainty in the first analysis, the probability of decision reversal was high under repeated testing frameworks. Conclusion: Early safety signals may reflect statistical noise. Evaluating the range of confidence intervals and estimating decision reversal probabilities provide meaningful insight into early results. Formal frameworks for uncertainty should guide decisions about interim data reporting, especially when findings may influence clinical or regulatory action.


  • An Example to Illustrate Randomized Trial Estimands and Estimators

    by Linda J. Harrison, Sean S. Brummel

    Recently, the International Conference on Harmonisation finalized an estimand framework for randomized trials that was adopted by regulatory bodies worldwide. The framework introduced five strategies for handling post-randomization events; namely the treatment policy, composite variable, while on treatment, hypothetical and principal stratum estimands. We describe an illustrative example to elucidate the difference between these five strategies for handling intercurrent events and provide an estimation technique for each. Specifically, we consider the intercurrent event of treatment discontinuation and introduce potential outcome notation to describe five estimands and corresponding estimators: 1) an intention-to-treat estimator of the total effect of a treatment policy; 2) an intention-to-treat estimator of a composite of the outcome and remaining on treatment; 3) a per-protocol estimator of the outcome in individuals observed to remain on treatment; 4) a g-computation estimator of a hypothetical scenario that all individuals remain on treatment; and 5) a principal stratum estimator of the treatment effect in individuals who would remain on treatment under the experimental condition. Additional insight is provided by defining situations where certain estimands are equal, and by studying the while on treatment strategy under repeated outcome measures. We highlight relevant causal inference literature to enable adoption in practice.


  • Open Access

    The Impact of Regular Screening and Lifestyle Modification on Cardiovascular Disease Risk Factors in South African Women Living With HIV

    by Sherika Hanley, Dhayendre Moodley, Mergan Naidoo, Sean S. Brummel

    Background: The Integration of cardiovascular disease SCreening and prevention in the HIV MAnagement plan for women of reproductive age study set out to determine the effectiveness of screening and lifestyle modification in modifying cardiovascular disease (CVD) risk factors in women living with HIV (WLHIV). Methods: In this prospective, quasiexperimental, intervention study, WLHIV aged 18–5.6 mmol/L in the I-arm and C-arm were 2.7% (4/149) and 13.3% (16/120) respectively (risk ratio 0.2; 95% CI: 0.069 to 0.646; P < 0.01). High-density lipoprotein improved with the intervention arm from baseline to EOS (95% CI: −0.157 to −0.034; P < 0.05). Conclusions: Although there was no significant difference in the prevalence of metabolic syndrome between study arms, we observed decreased blood glucose levels in the I-arm compared with the C-arm and improved high-density lipoprotein within the I-arm, following lifestyle modification and regular screening for CVD risk factors in WLHIV.


  • Open Access

    Data from Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers

    by Susan L. Neuhausen, Sean Brummel, Yuan Chun Ding, Linda Steele, Katherine L. Nathanson, Susan Domchek, Timothy R. Rebbeck, Christian F. Singer, Georg Pfeiler, Henry T. Lynch, et al.

  • Open Access

    Data from Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers

    by Susan L. Neuhausen, Sean Brummel, Yuan Chun Ding, Linda Steele, Katherine L. Nathanson, Susan Domchek, Timothy R. Rebbeck, Christian F. Singer, Georg Pfeiler, Henry T. Lynch, et al.

  • Analyzing Longitudinally Collected Viral Load Measurements in Youth With Perinatally Acquired HIV Infection: Problems and Possible Remedies

    by Sean S Brummel, Russell B Van Dyke, Kunjal Patel, Murli Purswani, George R Seage, Tzy-Jyun Yao, Rohan Hazra, Brad Karalius, Paige L Williams, for the Pediatric HIV/AIDS Cohort Study

    Human immunodeficiency virus (HIV) viral load (VL) is an important quantitative marker of disease progression and treatment response in people living with HIV infection, including children with perinatally acquired HIV. Measures of VL are often used to predict different outcomes of interest in this population, such as HIV-associated neurocognitive disorder. One popular approach to summarizing historical viral burden is the area under a time-VL curve (AUC). However, alternative historical VL summaries (HVS) may better answer the research question of interest. In this article, we discuss and contrast the AUC with alternative HVS, including the time-averaged AUC, duration of viremia, percentage of time with suppressed VL, peak VL, and age at peak VL. Using data on youth with perinatally acquired HIV infection from the Pediatric HIV/AIDS Cohort Study Adolescent Master Protocol, we show that HVS and their associations with full-scale intelligence quotient depend on when the VLs were measured. When VL measurements are incomplete, as can be the case in observational studies, analysis results may be subject to selection bias. To alleviate bias, we detail an imputation strategy, and we present a simulation study demonstrating that unbiased estimation of a historical VL summary is possible with a correctly specified imputation model.